We are live on ! Find out more
BBA

Baker Bros. Advisors Portfolio holdings

AUM $17.4B
1-Year Est. Return 131.5%
This Fund
S&P 500
This Quarter Est. Return
+3.34%
1 Year Est. Return
+131.5%
3 Year Est. Return
+336.81%
5 Year Est. Return
+553.16%
10 Year Est. Return
+4,134.93%
AUM
$17.4B
AUM Growth
+$71.8M
Cap. Flow
-$218M
Cap. Flow %
-1.26%
Top 10 Hldgs %
90.2%
Holding
115
New
7
Increased
18
Reduced
11
Closed
14

Top Buys

Rank Stock Value
1
ROIV icon
Roivant Sciences
ROIV
+$27.7M
2
ABCL icon
AbCellera Biologics
ABCL
+$26.2M
3
RARE icon
Ultragenyx Pharmaceutical
RARE
+$23.1M
4
DNLI icon
Denali Therapeutics
DNLI
+$21.2M
5
GLUE icon
Monte Rosa Therapeutics
GLUE
+$12.2M

Top Sells

Rank Stock Value
1
ARGX icon
argenx
ARGX
+$63.1M
2
KDNY
Chinook Therapeutics, Inc. Common Stock
KDNY
+$55.9M
3
DICE
DICE Therapeutics, Inc. Common Stock
DICE
+$48.1M
4
IMGN
Immunogen Inc
IMGN
+$28.7M
5
ANAB icon
AnaptysBio
ANAB
+$12.8M

Sector Composition

Rank Sector Weight
1 Healthcare 99.2%
2 Financials 0.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SGEN
1
DELISTED
Seagen Inc. Common Stock
SGEN
$9.45B 54.48%
44,554,162
– –
ONC
2
BeOne Medicines Ltd
ONC
$34.1B
$2.1B 12.1%
11,668,897
– –
INCY icon
3
Incyte
INCY
$25.3B
$2.09B 12.05%
36,178,566
+510
+0% +$32.1K
ACAD icon
4
Acadia Pharmaceuticals
ACAD
$4.46B
$893M 5.15%
42,864,612
– –
BMRN icon
5
BioMarin Pharmaceuticals
BMRN
$12B
$337M 1.94%
3,810,248
– –
MDGL icon
6
Madrigal Pharmaceuticals
MDGL
$12.5B
$226M 1.3%
1,545,113
– –
RYTM icon
7
Rhythm Pharmaceuticals
RYTM
$7.38B
$154M 0.89%
6,702,349
+204,082
+3% +$4.57M
ROIV icon
8
Roivant Sciences
ROIV
$23.9B
$139M 0.8%
11,877,171
+2,448,579
+26% +$27.7M
IMCR icon
9
Immunocore
IMCR
$1.68B
$131M 0.75%
2,520,731
– –
AKRO
10
DELISTED
Akero Therapeutics
AKRO
$120M 0.69%
2,368,378
– –
ABCL icon
11
AbCellera Biologics
ABCL
$1.63B
$95.5M 0.55%
20,763,323
+4,313,143
+26% +$26.2M
BCRX icon
12
BioCryst Pharmaceuticals
BCRX
$2.44B
$90M 0.52%
12,710,818
– –
REPL icon
13
Replimune Group
REPL
$439M
$78.3M 0.45%
4,578,280
– –
TRDA icon
14
Entrada Therapeutics
TRDA
$241M
$76.9M 0.44%
4,865,819
– –
RVMD icon
15
Revolution Medicines
RVMD
$38.3B
$74.5M 0.43%
2,691,493
– –
ARGX icon
16
argenx
ARGX
$55.2B
$74.3M 0.43%
151,215
-128,944
-46% -$63.1M
SWTX
17
DELISTED
SpringWorks Therapeutics
SWTX
$69.4M 0.4%
2,999,846
– –
KYMR icon
18
Kymera Therapeutics
KYMR
$8.68B
$66M 0.38%
4,750,400
+375,060
+9% +$7.54M
IMTX icon
19
Immatics
IMTX
$1.18B
$65.3M 0.38%
5,640,816
– –
MRTX
20
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$61.4M 0.35%
1,409,784
– –
KNSA icon
21
Kiniksa Pharmaceuticals
KNSA
$6.13B
$48.8M 0.28%
2,809,577
– –
RARE icon
22
Ultragenyx Pharmaceutical
RARE
$2.52B
$48.7M 0.28%
1,366,547
+583,488
+75% +$23.1M
DNLI icon
23
Denali Therapeutics
DNLI
$3.8B
$47.3M 0.27%
2,292,003
+836,681
+57% +$21.2M
PRLD icon
24
Prelude Therapeutics
PRLD
$360M
$31.3M 0.18%
10,123,824
– –
KOD icon
25
Kodiak Sciences
KOD
$2.43B
$31.2M 0.18%
17,310,490
– –
1
2 3 4 5

Similar funds

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
CM
Caption Management Oklahoma City, Oklahoma $17.1B AUM 70.99% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
ASRS
Arizona State Retirement System Phoenix, Arizona $17.1B AUM 30.52% 1-Year Est. Return
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return
VMPIC
Varma Mutual Pension Insurance Co Helsinki, Finland $17B AUM 24.09% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
BCIM
British Columbia Investment Management Victoria, British Columbia, Canada $17B AUM 31.69% 1-Year Est. Return

Baker Bros. Advisors's Q3 2023 Portfolio in Review

As of Q3 2023, Baker Bros. Advisors held 115 positions worth $17.4B, up 0.42% from $17.3B the previous quarter. Its ten largest holdings account for 90% of the portfolio.

Baker Bros. Advisors's Q3 2023 filing shows 7 new, 18 increased, 11 reduced and 14 closed positions. Its largest new stake was Morphic Holding, Inc. Common Stock: 215,800 shares worth $4.94M. The largest sale was argenx, an estimated $63.1M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 99% a quarter earlier, followed by Financials.

  • Baker Bros. Advisors's largest Q3 2023 buy was Morphic Holding, Inc. Common Stock: 215,800 shares worth $4.94M.
  • Baker Bros. Advisors added most to Roivant Sciences in Q3 2023, an estimated $27.7M increase.
  • Baker Bros. Advisors's biggest Q3 2023 reduction was argenx, cutting an estimated $63.1M.
  • Baker Bros. Advisors fully exited Chinook Therapeutics, Inc. Common Stock in Q3 2023, selling an estimated $55.9M.
  • Baker Bros. Advisors's ten largest holdings make up 90% of its $17.4B portfolio in Q3 2023.
  • Baker Bros. Advisors opened 7 new positions and closed 14 in Q3 2023.
  • Baker Bros. Advisors's portfolio value rose 0.42% quarter-over-quarter to $17.4B.

Based on Baker Bros. Advisors's 13F filing for Q3 2023, filed 14 Nov 2023.